Home > Resources > Company Profiles > Northwest BioTherapeutics

Northwest BioTherapeutics (NWBO)

EMAIL
PRINT
SHARE
TEXT SIZE:
SHARE
Send a copy to me

Separate multiple email addresses (max 20) with commas.

0/1500
Dr. Alton L. Boynton, Ph.D. , CEO/President/Director/Secretary/Chief Scientific Officer/COO/Founder
Industry: Healthcare
OPEN
LAST
$
PREV CLOSE
CHANGE
VOLUME


Overview
News
People
Financials

Company Information

Dr. Alton L. Boynton, Ph.D., CEO/President/Director/Secretary/Chief Scientific Officer/COO/Founder

7600 Wisconsin Ave

Suite 750

Bethesda, MD 20814

US Map it

Phone: (240) 497-9024

Fax: (425) 608-3026

www.nwbio.com



Overview

A development stage biotechnology company that focuses on discovering, developing, and commercializing immunotherapy products that safely generate and enhance immune system responses to treat cancer.

Employees

Number of Employees: 7
Revenue per Employee: $3,333

Board of Directors

Linda F. Powers, J.D., Chairman of the Board/Director

Financials

Quarterly
Annual

Income Statement 07/2008 04/2008 12/2007 09/2007
Sales 0 12 K. -497 K. -5.2 Mil.
Gross Operating Profit 0 -12 K. 507 K. 5.2 Mil.
Operating Income before D & A (EBITDA) -5.66 Mil. -6.98 Mil. -3.06 Mil. 1.59 Mil.
Total Income Before Interest Expenses (EBIT) -5.61 Mil. -7.38 Mil. -3.21 Mil. -3.22 Mil.
Total Net Income -5.62 Mil. -7.44 Mil. -3.91 Mil. -7.96 Mil.
Basic EPS, Total -0.13 0.38 -0.09 -5.56
Diluted EPS, Total -0.13 0.38 -0.09 -5.56

BALANCE STATEMENT 07/2008 04/2008 12/2007 09/2007
Cash and Equivalents 2.58 Mil. 7.86 Mil. 16.88 Mil. 25.39 Mil.
Total Assets 3.37 Mil. 8.68 Mil. 17.32 Mil. 26.02 Mil.
Total Liabilities 2.27 Mil. 2.9 Mil. 6.76 Mil. 10.77 Mil.
Total Capitalization 1.23 Mil. 5.81 Mil. 10.57 Mil. 15.26 Mil.

Cash Flow 07/2008 04/2008 12/2007 09/2007
Net Cash From Continuing Operations -5.11 Mil. -14.6 Mil. -10.42 Mil. -3.19 Mil.
Net Cash From Investing Activities -128 K. -24 K. -15 K. -11 K.
Net Cash From Financing Activities 0 22.18 Mil. 27.01 Mil. 28.29 Mil.
Net Change in Cash & Cash Equivalents -5.28 Mil. 7.55 Mil. 16.57 Mil. 25.09 Mil.

powered by Interactive Data

Income Statement 2008 2007 2006 2005
Sales -5.74 Mil. -1.99 Mil. -2.9 Mil. -1.52 Mil.
Gross Operating Profit 5.75 Mil. 2.07 Mil. 3.02 Mil. 1.91 Mil.
Operating Income before D & A (EBITDA) -10.2 Mil. -3.98 Mil. -3.45 Mil. -4.56 Mil.
Total Income Before Interest Expenses (EBIT) -15.63 Mil. 1.17 Mil. -6.42 Mil. -6.74 Mil.
Total Net Income -21.26 Mil. -1.4 Mil. -9.94 Mil. -8.51 Mil.
Basic EPS, Total -2.38 -0.45 -7.8 -6.75
Diluted EPS, Total -2.38 -0.45 -7.8 -6.75

BALANCE STATEMENT 2008 2007 2006 2005
Cash and Equivalents 7.86 Mil. 307 K. 352 K. 248 K.
Total Assets 8.68 Mil. 455 K. 544 K. 410 K.
Total Liabilities 2.9 Mil. 6.45 Mil. 12.05 Mil. 5.76 Mil.
Total Capitalization 5.81 Mil. -5.95 Mil. -11.42 Mil. -5.22 Mil.

Cash Flow 2008 2007 2006 2005
Net Cash From Continuing Operations -14.6 Mil. -6.93 Mil. -4.18 Mil. -4.42 Mil.
Net Cash From Investing Activities -24 K. 17 K. 50 K. 161 K.
Net Cash From Financing Activities 22.18 Mil. 6.87 Mil. 4.24 Mil. 4.26 Mil.
Net Change in Cash & Cash Equivalents 7.55 Mil. -45 K. 104 K. -7 K.

powered by Interactive Data







Related Companies by Market Cap
Company Name
Price
Change
Market Cap
Pipex Pharmaceuticals, Incorporated
85.99 Mil.
Peregrine Pharmaceuticals, Inc.
85.96 Mil.
Cell Therapeutics, Incorporated
85.03 Mil.
Nuvelo, Incorporated
84.89 Mil.

Company Profile Change Request

The data provided in our company profiles comes from third party information providers.

Also in Portfolio.com
Most Read
Most Emailed
Recently Commented